Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 12 February 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2023.

Under the programme initiated 6 February 2024, Novo Nordisk will repurchase B shares for an amount up to DKK 2.1 billion in the period from 6 February 2024 to 30 April 2024.

Since the announcement of the programme, the following transactions have been made:

  Number ofB shares Averagepurchase price Transactionvalue, DKK
6 February 2024 44,000 815.84 35,896,842
7 February 2024 45,000 810.12 36,455,606
8 February 2024 45,000 820.55 36,924,925
9 February 2024 45,000 829.51 37,327,950
Accumulated under the programme 179,000   146,605,323

The details for each transaction made under the share repurchase programme are published on

Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 7,337,347 B shares in the period from 29th January 2024 to 9th February 2024. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 46,719,707 B shares of DKK 0.10 as treasury shares, corresponding to 1.0% of the share capital. The total amount of A and B shares in the company is 4,510,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 09 February 2024, Novo Nordisk has since 6 February 2024 repurchased a total of 179,000 B shares at an average share price of DKK 819.02 per B share equal to a transaction value of DKK 146,605,323.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit, Facebook, Instagram, X, LinkedIn and YouTube.

Contact for further information

Ambre James-Brown +45 3079 Liz Skrbkova (US)+1 609 917
Daniel Muusmann Bohsen+45 3075 2175 Jacob Martin Wiborg Rode+45 3075
David Heiberg Landsted +45 3077 6915 Mark Joseph Root (US) +1 848 213
Sina Meyer +45 3075 6656 Frederik Taylor Pitter +45 3075 8259

Company announcement No 14 / 2024


  • CA240212-share repurchase
  • 240212 safe harbour transaction details
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Mär 2024 bis Apr 2024 Click Here for more Novo Nordisk Charts.
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Apr 2023 bis Apr 2024 Click Here for more Novo Nordisk Charts.